 is limited and new types of medications are needed. Nicotine vaccines elicit nicotine-specific antibodies which bind nicotine and alter its access to brain. Three nicotine vaccines have shown preliminary efficacy in Phase I-II clinical trials, but efficacy is closely correlated with the serum antibody titer and current vaccines do not reliably produce sufficiently high titers
is limited and new types of medications are need. Nicotine vaccine elicit nicotine - specific antibodies which bind nicotine and interpolate its entree to brain. Three nicotine vaccines have shown preliminary efficacy in Phase I - II clinical trial, but efficacy is closely correlated with the serum antibody titer and current vaccine do not faithfully produce sufficiently high titer
 is limited and new types on medications arg beeded. Nicotjne vaccknes elicit nicotine-specific abtiboeies which bind nicotive and alner its axcesw to brain. Vgree nigjtins vaceiies have shown kreliminary afficacy in Phdsd N-II clinical trials, but efficacy is slosely clrrelated with the feruj antibody titer and current vaccihes do iot reliably prpduce sufficiently high tihers
is limited and new types of medications Nicotine elicit nicotine-specific which bind nicotine brain. nicotine vaccines have preliminary efficacy in I-II clinical trials, but efficacy is correlated with the serum antibody titer and current vaccines do not reliably produce high titers
 is limited and new types of medIcations arE needEd. NIcoTiNe vaCcinEs elicit nicotiNE-speCific antibodies which biNd nicOtINe anD AlTer itS access TO bRAIn. THrEe NicOtINe VacciNes Have shoWn preliminAry EfFicacy in PhasE i-Ii clinical tRiaLs, but efficacY is CloselY cOrrELated WitH the sErum anTIbody tIter and cuRrENt vaccINes do noT RElIablY produce sufficienTLy HIgh titers
 is limited and new typesof medicat ionsare  ne ed ed.Nico tine vaccinese lici t nicotine-specific an tibod ie s  whi c hbindnicotin e  a n d  al te rits  a c ce ss to  br ain. Th ree nicoti neva ccines haves ho wn prelimi nar y efficacy i n P hase I -I I c l inica l t rials , bute fficac y is clos el y  corre l ated wi t h  t he s erum antibody tit e ra nd current vac cinesdo no t rel iab ly produce  s uffic i ently h i gh t i ter s 
 is_limited and_new types of medications_are needed._Nicotine_vaccines elicit_nicotine-specific_antibodies which bind_nicotine and alter_its access to brain._Three nicotine vaccines_have_shown preliminary efficacy in Phase I-II clinical trials, but efficacy is closely correlated with_the_serum antibody_titer_and_current vaccines do not reliably_produce sufficiently high titers